



Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Plot No. 109-D, Road No. 29, Sion (East),
Mumbai - 400 022. (India)
Tel.: 022-2407 2249 / 2401 9025 (30 Lines)
Fax : 022-2407 3462 / 2407 0144
Email : admin@aartidrugs.com
Website : www.aartidrugs.com
CIN NO : L37060MH1984PLC055433

AARTI DRUGS LIMITED

STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31ST MARCH, 2015

(Rs. in lacs except for share data)

PART I

Sr. No.	Particulars	Standalone					Consolidated
		Quarter Ended		Year Ended		Year Ended	
		31st Mar, 2015 (Audited)	31st Dec, 2014 (Audited)	31st Mar, 2014 (Audited)	31st Mar, 2015 (Audited)	31st Mar, 2014 (Audited)	31st Mar, 2015 (Audited)
1	Income from Operations						
	(a) Gross Sales / Income from Operations	30,067	28,119	30,386	116,994	104,435	117,960
	Less : Excise Duty & Sales Tax	2,306	2,161	2,207	8,546	7,441	8,533
	(a) Net Sales / Income from Operations (Net Of Excise Duty & Sales Tax)	27,761	25,958	28,179	108,448	96,994	109,427
	(b) Other Operating Income	76	150	124	274	181	261
	Total income from operations (net)	27,837	26,107	28,304	108,722	97,175	109,688
2	Expenditure						
	(a) Cost of materials consumed	15,630	17,638	15,667	67,844	57,082	69,019
	(b) Purchase of stock-in-trade	1,175	1,602	1,756	8,699	8,602	8,699
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	2,139	(1,964)	2,383	(2,358)	569	(2,730)
	(d) Employee benefits expense	1,024	918	862	3,730	3,241	3,793
	(e) Depreciation and Amortisation Expense	809	771	759	3,066	2,812	3,102
	(f) Other expenses	3,578	3,536	3,366	13,911	13,046	14,005
	Total expenses	24,355	22,500	24,793	94,893	85,351	95,888
3	Profit from Operations before Other Income, finance costs and exceptional items (1-2)	3,482	3,608	3,510	13,829	11,823	13,800
4	Other Income	0	64	1	65	2	65
5	Profit from ordinary activities before finance cost and exceptional items (3+4)	3,482	3,672	3,511	13,894	11,825	13,865
6	Finance costs (interest)	976	986	917	3,888	3,349	3,893
7	Profit from ordinary activities after finance cost but before Exceptional Items (5-6)	2,506	2,686	2,595	10,006	8,476	9,972
8	Exceptional Items	-	-	-	-	-	-
9	Profit from Ordinary Activities before Tax (7-8)	2,506	2,686	2,595	10,006	8,476	9,972
10	Tax Expenses	620	411	399	2,247	2,397	2,247
	Provision for Taxation - Current	528	495	630	2,100	2,300	2,100
	- MAT Credit Entitlement	(48)	(31)	-	(100)	-	(100)
	- Earlier year	-	(153)	(321)	(153)	(253)	(153)
	Provision for Deferred Taxation	140	100	90	400	350	400
11	Net profit from ordinary Activities after Tax (9-10)	1,886	2,275	2,195	7,760	6,080	7,725
12	Extraordinary items	-	-	-	-	92	-
13	Net Profit for the Period (11+12)	1,886	2,275	2,195	7,760	6,171	7,725
14	Paid-up Equity Share Capital of Rs.10/- each	2,422	1,211	1,211	2,422	1,211	2,422
15	Reserves & Surplus (excluding revaluation reserves)				27,949	23,880	28,394
16	Earning per share (of Rs. 10 /- each) (not annualised)						
	(a) Basic & Diluted (before extraordinary items)	7.79	9.40	9.07	32.04	25.10	31.90
	(b) Basic & Diluted (after extraordinary items)	7.79	9.40	9.07	32.04	25.48	31.90

PART II

A	PARTICULARS OF SHAREHOLDING						
1	Public shareholding						
	-Number of Shares	9,662,736	4,769,701	4,890,428	9,662,736	4,890,428	9,662,736
	-Percentage of Total Shareholding	39.90	39.39	40.39	39.90	40.39	39.90
2	Promoters & Promoter Group shareholding						
	a) Pledged/Encumbered						
	- Number of Shares	Nil	Nil	Nil	Nil	Nil	Nil
	-Percentage of shares(as a % of the total shareholding of promoter and promoter group)	Nil	Nil	Nil	Nil	Nil	Nil
	-Percentage of shares(as a % of the total Share capital of the company)	Nil	Nil	Nil	Nil	Nil	Nil
	b) Non-encumbered						
	- Number of Shares	14,554,364	7,338,849	7,218,122	14,554,364	7,218,122	14,554,364
	-Percentage of shares(as a % of the total Shareholding of promoter and promoter group)	100	100	100	100	100	100
	-Percentage of shares(as a % of the total Share capital of the company)	60.10	60.61	59.61	60.10	59.61	60.10

B	INVESTOR COMPLAINTS	Qtr Ended 31st March, 2015
	Pending at the beginning of the quarter	0
	Received during the quarter	3
	Disposed of during the quarter	3
	Remaining unresolved at the end of the quarter	0



Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Plot No. 109-D, Road No. 29, Sion (East),
Mumbai - 400 022. (India)
Tel.: 022-2407 2249 / 2401 9025 (30 Lines)
Fax : 022-2407 3462 / 2407 0144
Email : admin@aartidrugs.com
Website : www.aartidrugs.com
CIN NO : L37060MH1984PLC055433

STATEMENT OF ASSETS AND LIABILITIES AS AT 31ST MARCH, 2015 (Rs. in lacs)

Sr. No.	Particulars	Standalone		Consolidated
		As at 31st March, 2015	As at 31st March, 2014	As at 31st March, 2015
A	EQUITY AND LIABILITIES			
1	Shareholder Funds			
	(a) Share Capital	2,422	1,211	2,422
	(b) Reserves and surplus	27,949	23,880	28,394
	Total - Shareholders's funds	30,370	25,090	30,815
2	Non-current liabilities			
	(a) Long - term borrowings	15,147	7,664	16,347
	(b) Deferred tax liabilities (net)	3,501	3,101	3,502
	(c) Other long - term liabilities	1,205	1,151	1,225
	(d) Long - term provisions	29	-	29
	Total - Non - current liabilities	19,883	11,916	21,103
3	Current liabilities			
	(a) Short - term borrowings	25,127	26,560	25,243
	(b) Trade payables	15,019	15,018	16,672
	(c) Other current liabilities	4,119	4,418	4,153
	(d) Short - term provisions	2,176	1,971	2,208
	Total - current liabilities	46,440	47,967	48,276
	TOTAL- EQUITY AND LIABILITIES	96,693	84,974	100,194
B	ASSETS			
1	Non-current assets			
	(a) Fixed assets (including CWIP)	44,483	38,084	46,452
	(b) Non - current investments	1,111	462	463
	(c) Long - term loans and advances	424	704	724
	Total - Non - current assets	46,019	39,250	47,640
2	Current assets			
	(a) Inventories	15,336	12,673	16,420
	(b) Trade receivables	30,759	27,652	31,427
	(c) Cash and cash equivalents	343	440	358
	(d) Short - term loans and advances	1,745	2,221	1,765
	(e) Other non - current assets	2,491	2,739	2,585
	Total - current assets	50,674	45,724	52,554
	TOTAL - ASSETS	96,693	84,974	100,194

Notes:

- The above results, reviewed by the Audit Committee, have been taken on record by the Board of Directors at their meeting held on 20th May, 2015
- The Board of Directors has recommended a Final Dividend of Rs. 3/- per share on 2,42,17,100 Equity Shares of Rs. 10/- each fully paid-up for the Financial Year 2014-15.
- The Board of Directors allotted on 26th March, 2015, 1,21,08,550 fully paid up equity shares of face value Rs. 10/ each in the ratio of 1:1, pursuant to shareholders' approval. The said bonus shares were listed for trading on BSE and NSE from 30th March, 2015. Earnings per Share has been adjusted for previous periods presented in accordance with Accounting Standard 20 - Earnings per share.
- Company is operating as a single segment Company, engaged in Pharmaceuticals business.
- Figures for the previous period have been regrouped or rearranged wherever necessary.

Place: Mumbai
Date: 20.05.2015

For and on behalf of the Board
For AARTI DRUGS LIMITED

Harshit M. Savla
HARSHIT M. SAVLA
(Jt. Managing Director)



**Auditor's Report on Quarterly and Annual Financial Results of Aarti Drugs Limited
Pursuant to the Clause 41 of the Listing Agreement**

To
Board of Directors of Aarti Drugs Limited

We have audited the quarterly financial results of Aarti Drugs Limited for the quarter ended 31st March, 2015 and the annual results for the year ended 31st March, 2015 attached herewith, being submitted by the company pursuant to the requirement of clause 41 of the Listing Agreement except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. These quarterly financial results have been prepared on the basis of the interim financial statements and annual financial results have been prepared on the basis of the annual financial statements, which are the responsibility of the company's management. Our responsibility is to express an opinion on these financial results based on our audit of such interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard (AS) 25, Interim Financial Reporting, specified under section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014 and other accounting principles generally accepted in India.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatements. An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.





In our opinion and to the best of our information and according to the explanations given to us these quarterly financial results as well as the annual results:

- (i) are presented in accordance with the requirements of clause 41 of the Listing Agreement in this regard; and
- (ii) give a true and fair view of the net profit and other financial information for the quarter ended 31st March, 2015 as well as the annual results from 1st April, 2014 to 31st March, 2015.

Further, we also report that we have, on the basis of the books of account and other records and information and explanations given to us by the management, verified the number of shares as well as percentage of shareholdings in respect of aggregate amount of non promoter shareholdings, as furnished by the company in terms of clause 35 of the Listing Agreement and found the same to be correct.

For GOKHALE & SATHE
CHARTERED ACCOUNTANTS



CA TEJAS PARIKH
PARTNER
M.No. 123215
Firm Registration No.: 103264W

Place: Mumbai,

Dated: May 20, 2015



Auditors' Report on Consolidated Annual Results of Aarti Drugs Limited Pursuant to the
Clause 41 of the Listing Agreement

To
Board of Directors of Aarti Drugs Limited

We have audited the consolidated annual results of Aarti Drugs Limited for the year ended 31st March, 2015 attached herewith, being submitted by the company pursuant to the requirement of clause 41 of the Listing Agreement except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. These consolidated annual financial results have been prepared from consolidated Annual Financial statements, which are the responsibility of the company's management. Our responsibility is to express an opinion on these financial results based on our audit of such financial statements, which have been prepared in accordance with the Accounting Standards, issued by the Institute of Chartered Accountants of India and other accounting principles generally accepted in India.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

We did not audit the financial statements of the subsidiary, whose financial statements reflect total assets of Rs. 44,35,76,098 as at 31st March, 2015 and total revenues of Rs. 13,28,96,439 for the year then ended. These financial statements have been audited by other auditor, whose reports have been furnished to us and our opinion, insofar as it relates to the amounts included in respect of the subsidiary and associate, is based solely on the report of the other auditor.

In our opinion and to the best of our information and according to the explanations given to us these consolidated financial results:





- (i) include financial results of subsidiary, Pinnacle Life Sciences Private Limited
- (ii) have been presented in accordance with the requirements of clause 41 of the Listing Agreement in this regard; and
- (iii) give a true and fair view of the consolidated net profit and other financial information for the annual results for the period from 1st April, 2014 to 31st March, 2015

Further, we also report that we have, on the basis of the books of account and other records and information and explanations given to us by the management, also verified the consolidated number of shares as well as percentage of shareholdings in respect of aggregate amount of consolidated public shareholdings, as furnished by the company in terms of clause 35 of the Listing Agreement and found the same to be correct.

**For GOKHALE & SATHE
CHARTERED ACCOUNTANTS**



**TEJAS PARIKH
PARTNER
M.No. 123215**

Firm Registration No.: 103264W

Place : Mumbai,
Dated: May 20, 2015